MA45690A - Anticorps anti-tgfb, méthodes et utilisations - Google Patents

Anticorps anti-tgfb, méthodes et utilisations

Info

Publication number
MA45690A
MA45690A MA045690A MA45690A MA45690A MA 45690 A MA45690 A MA 45690A MA 045690 A MA045690 A MA 045690A MA 45690 A MA45690 A MA 45690A MA 45690 A MA45690 A MA 45690A
Authority
MA
Morocco
Prior art keywords
methods
tgfb antibodies
tgfb
antibodies
Prior art date
Application number
MA045690A
Other languages
English (en)
Inventor
Gregory J Carven
Thomas Schurpf
Katherine Turner
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA45690A publication Critical patent/MA45690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045690A 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations MA45690A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US201662371355P 2016-08-05 2016-08-05

Publications (1)

Publication Number Publication Date
MA45690A true MA45690A (fr) 2019-05-22

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045690A MA45690A (fr) 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations

Country Status (13)

Country Link
US (2) US20190292254A1 (fr)
EP (1) EP3484499A4 (fr)
JP (2) JP7128801B2 (fr)
KR (1) KR102577551B1 (fr)
CN (1) CN110049773A (fr)
AU (1) AU2017294772B2 (fr)
BR (1) BR112019000621A2 (fr)
CA (1) CA3030862A1 (fr)
IL (1) IL264161B2 (fr)
MA (1) MA45690A (fr)
MX (1) MX419976B (fr)
SG (1) SG11201900200XA (fr)
WO (1) WO2018013939A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035550B1 (ru) 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
KR20250011248A (ko) 2016-03-11 2025-01-21 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
LT3677278T (lt) 2018-07-11 2022-01-10 Scholar Rock, Inc. Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas
TW202019957A (zh) * 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
AU2019302679A1 (en) 2018-07-11 2021-02-11 Scholar Rock, Inc. High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
TW202043267A (zh) 2019-01-30 2020-12-01 美商供石公司 TGFβ之LTBP複合物專一性抑制劑及其用途
CA3155172A1 (en) * 2019-10-25 2021-04-29 Shinko HAYASHI Combination of anti-garp antibody and immunomodulator
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
KR20230169936A (ko) * 2021-01-18 2023-12-18 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 Garp 단백질 항체 및 이의 적용
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
EP4348260A2 (fr) 2021-06-03 2024-04-10 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
EP4370148A1 (fr) 2021-07-14 2024-05-22 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
KR20240045310A (ko) * 2021-09-30 2024-04-05 베타 파머수티컬 컴퍼니 리미티드 이중특이성 항체 및 그 응용
JP2026504831A (ja) * 2023-01-09 2026-02-10 北京拓界生物医薬科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及びそれらの医薬的使用
WO2024164807A1 (fr) * 2023-02-06 2024-08-15 贝达药业股份有限公司 Anticorps multispécifique et son utilisation
JP2026507882A (ja) 2023-03-07 2026-03-06 スカラー ロック インコーポレイテッド 患者の抵抗性又は不応答性癌を治療するためのＴＧＦ－β阻害剤及びその使用
WO2025240343A1 (fr) 2024-05-13 2025-11-20 Scholar Rock, Inc. Inhibiteurs de tgf-bêta pour le traitement du cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0669929B1 (fr) 1992-11-13 2007-01-03 Immunex Corporation Ligand d'elk, une cytokine
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995028484A1 (fr) 1994-04-15 1995-10-26 Amgen Inc. Nouvelles proteines tyrosine kinases receptrices analogues a l'eph, du type hek5, hek7, hek8, hek11
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP2003203A1 (fr) 1996-12-23 2008-12-17 Immunex Corporation Ligand pour l'activateur des récepteurs du nf-kappa b, ligand est un membre de la superfamille de TNF
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
JP4587626B2 (ja) 1999-06-07 2010-11-24 イミュネックス・コーポレーション Ｔｅｋアンタゴニスト
WO2001016344A1 (fr) 1999-08-27 2001-03-08 Transgene S.A. Fibre adenovirale modifiee et utilisations
AU4721901A (en) 2000-02-25 2001-09-03 Immunex Corp Integrin antagonists
DE60143798D1 (de) * 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2006068953A2 (fr) * 2004-12-21 2006-06-29 Astrazeneca Ab Anticorps dirigés contre l'angiopoïétine 2 et leurs utilisations
BRPI0613784A2 (pt) * 2005-07-21 2011-02-01 Abbott Lab expressão de gene múltipla incluindo constructos sorf e métodos com poliproteìnas, pro-proteìnas e proteólise
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8980257B2 (en) * 2010-05-18 2015-03-17 Medical & Biological Laboratories Co., Ltd. Antibody being capable of binding to transforming growth factor alpha and having growth-suppressing activity on cancers having Ras gene mutation
KR102130865B1 (ko) * 2012-10-02 2020-08-05 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물
SMT202100008T1 (it) * 2013-05-06 2021-03-15 Scholar Rock Inc Composizioni e metodi per la modulazione di fattore di crescita
EA035550B1 (ru) * 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US11597778B2 (en) * 2015-04-07 2023-03-07 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to ADAMTS13 and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
KR20250011248A (ko) * 2016-03-11 2025-01-21 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도

Also Published As

Publication number Publication date
SG11201900200XA (en) 2019-02-27
US12281159B2 (en) 2025-04-22
JP7128801B2 (ja) 2022-08-31
CA3030862A1 (fr) 2018-01-18
JP2022153406A (ja) 2022-10-12
AU2017294772B2 (en) 2024-05-02
AU2017294772A1 (en) 2019-01-31
IL264161B1 (en) 2025-02-01
CN110049773A (zh) 2019-07-23
KR20190034560A (ko) 2019-04-02
IL264161B2 (en) 2025-06-01
IL264161A (en) 2019-02-28
WO2018013939A1 (fr) 2018-01-18
EP3484499A1 (fr) 2019-05-22
EP3484499A4 (fr) 2020-05-13
BR112019000621A2 (pt) 2019-04-24
US20190292254A1 (en) 2019-09-26
US20210277100A1 (en) 2021-09-09
JP2019524094A (ja) 2019-09-05
MX419976B (es) 2025-01-14
KR102577551B1 (ko) 2023-09-11
MX2019000514A (es) 2019-07-12

Similar Documents

Publication Publication Date Title
EP3484499A4 (fr) Anticorps anti-tgfb, méthodes et utilisations
EP3658589C0 (fr) Anticorps anti-sirp-alpha et méthodes associées
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3356416A4 (fr) Anticorps anti-pd-1 et ses utilisations
EP3411412A4 (fr) Technologie fit-immunoglobuline et ses utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3400243A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations